Current Report Filing (8-k)
03 Mai 2023 - 10:40PM
Edgar (US Regulatory)
0001533615
false
0001533615
2023-05-03
2023-05-03
0001533615
us-gaap:CommonStockMember
2023-05-03
2023-05-03
0001533615
us-gaap:SeriesAPreferredStockMember
2023-05-03
2023-05-03
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 3, 2023 (May 3, 2023)
Global Medical REIT Inc.
(Exact name of registrant as specified in its charter)
Maryland |
001-37815 |
46-4757266 |
(State
or Other Jurisdiction
of Incorporation) |
(Commission
File Number) |
(I.R.S.
Employer
Identification No.) |
7373 Wisconsin Avenue, Suite 800
Bethesda, MD
20814
(Address of Principal Executive Offices)
(Zip Code)
(202) 524-6851
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class: |
|
Trading Symbols: |
|
Name of each exchange on which registered: |
Common Stock, par value $0.001 per share |
|
GMRE |
|
NYSE |
Series A Preferred Stock, par value $0.001 per share |
|
GMRE PrA |
|
NYSE |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 Results of Operations and Financial Condition.
On May 3, 2023, Global Medical REIT Inc.
(the “Company”) announced its financial position as of March 31, 2023 and operating results for the three months ended
March 31, 2023 and other related information (the “Earnings Release”). The Company also posted its First Quarter 2023
Earnings Supplemental (the “Supplemental”) to the Company’s website at www.globalmedicalreit.com. The Earnings
Release and Supplemental are furnished as Exhibit 99.1 and Exhibit 99.2, respectively, and are incorporated herein by reference.
The information included in this Item 2.02 of
this Current Report on Form 8-K, including the Earnings Release and Supplemental, shall not be deemed “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject
to the liabilities of that section, and shall not be incorporated by reference into any filing of the Company under the Securities Act
of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
*Furnished herewith
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Global Medical REIT Inc. |
|
|
|
|
By: |
/s/ Jamie A. Barber |
|
|
Jamie A. Barber |
|
|
Secretary and General Counsel |
Date: May 3, 2023
Global Med REIT (NYSE:GMRE-A)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
Global Med REIT (NYSE:GMRE-A)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025